Skip to main content
S&P 5007,807.24-0.06%DOW51,850.55+0.38%NASDAQ27,245.90-0.44%BTC$81,018.00-3.35%ETH$2,413.99-5.04%GOLD$4,184.60-0.14%OIL$93.25-0.52%
Smart Investors Daily
SID Premium
GE

NASDAQ · GERN

Geron Corporation

Healthcare · Biotechnology

$1.23

Down-$0.01 (-0.41%)

Updated Oct 13, 2026, 12:06 AM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
884.12M
P/E ratio
-11.55
Dividend yield
0.00%
52-week range
$1.04 – $2.01
Volume
5.64M
Avg. volume
7.6M

Price performance · GERN

GERN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

GERN closed at $1.23 after 20 trading sessions, down 10.58% for the selected period.

Last close
$1.23
Period change
-10.58%
Period low
$1.20
Period high
$1.37
Daily close
View OHLC price history
GERN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$1.22$1.26$1.21$1.2255.64M
Oct 8, 2026$1.205$1.22$1.17$1.2210.16M
Oct 7, 2026$1.21$1.215$1.185$1.205.14M
Oct 6, 2026$1.20$1.24$1.19$1.215.72M
Oct 5, 2026$1.20$1.23$1.18$1.216.37M
Oct 2, 2026$1.21$1.22$1.19$1.2014.72M
Oct 1, 2026$1.24$1.2479$1.19$1.2113.26M
Sep 30, 2026$1.26$1.27$1.23$1.239.44M
Sep 29, 2026$1.26$1.26$1.21$1.2412.5M
Sep 28, 2026$1.27$1.27$1.22$1.259.97M
Sep 25, 2026$1.26$1.27$1.24$1.2610.3M
Sep 24, 2026$1.23$1.27$1.20$1.266.41M
Sep 23, 2026$1.33$1.33$1.22$1.2410.93M
Sep 22, 2026$1.32$1.325$1.29$1.316.22M
Sep 21, 2026$1.30$1.31$1.28$1.305.9M
Sep 18, 2026$1.32$1.33$1.29$1.3017.24M
Sep 17, 2026$1.32$1.34$1.30$1.329.82M
Sep 16, 2026$1.32$1.33$1.27$1.2911.44M
Sep 15, 2026$1.37$1.37$1.30$1.3116.49M
Sep 14, 2026$1.36$1.395$1.344$1.3712.12M

Latest GERN news

The latest Smart Investors Daily articles mentioning GERN.

Stock researchCompany · Overview

GERN research

Overview

Company profile and research snapshot.

Company profile

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.89
Implied upside
—
Analysts
—
GERN recent ratings
DateFirmRatingTarget
Nov 5, 2025NeedhamBuy—
Jul 10, 2025Goldman SachsSell—
May 8, 2025ScotiabankSector Perform—
Mar 12, 2025HC Wainwright & Co.Neutral—
Mar 12, 2025NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 18, 2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective September 17, 2026, it granted stock options to purchase an aggregate of 821,250 shares of common stock to nine newly hired employees as an inducement material to such employees’ acceptance of employment with Geron. The stock options have an exercise price of $1

Yahoo · Sep 2, 2026

Geron to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference:Fireside Chat on Wednesday, September 9, 2026, at 8:00 a.m. ET in New York, NY H.C. Wainwright 28th Annual Global Investmen

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By